ONCOS C824

OncoC4 is a clinical-stage biopharmaceutical company focused on developing novel biologics for cancer treatment by targeting innate and adaptive immune checkpoints. Spun off from OncoImmune following its acquisition by Merck (MSD), the company leverages its PhD checkpoint platform to identify and develop antibodies that selectively deplete regulatory T cells in the tumor microenvironment while sparing them in healthy tissues. Its lead candidate, gotistobart (ONC-392), is a next-generation anti-CTLA-4 antibody currently in Phase 2/3 clinical trials for various solid tumors, including non-small cell lung cancer. OncoC4 aims to overcome the toxicity limitations of first-generation immunotherapy through its unique mechanism of pH-dependent recycling.